Sarepta Therapeutics Inc., a leader in precision genetic medicine, has announced new equity awards as part of its 2024 Employment Commencement Incentive Plan. On June 30, 2025, the company granted equity awards to 53 newly hired employees. These awards include options to purchase 22,016 shares of Sarepta's common stock and 317,317 restricted stock units (RSUs). The options are priced at $17.10 per share, matching the closing price of Sarepta's stock on the grant date. The options will vest over four years, with an initial 25% vesting after one year and the remainder vesting monthly. Similarly, the RSUs will vest annually over four years, contingent upon continued employment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.